Department of Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France.
Department of Rheumatology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France; Inserm U1035, Biothérapie des Maladies Génétiques et Cancers, University of Bordeaux, Bordeaux, France.
J Am Acad Dermatol. 2019 Feb;80(2):478-484. doi: 10.1016/j.jaad.2018.07.033. Epub 2018 Aug 7.
Skin pigmentation disorders in systemic sclerosis (SSc) have been sparsely described in the literature. Nevertheless, they could be a diagnostic and/or severity marker.
To assess the association between pigmentation disorders and systemic involvement in patients with SSc.
A total of 5 patterns of skin pigmentation disorders were defined: diffuse hyperpigmentation; hyperpigmentation of sun-exposed areas; hypopigmentation of the head, neck, and/or upper part of the chest; acral hypopigmentation; and diffuse hypopigmentation.
A total of 239 patients were included; 88 patients (36.8%) had skin pigmentation disorders as follows: diffuse hyperpigmentation and hyperpigmentation of sun-exposed areas in 38.6% (n = 34) and 27.3% (n = 24) of patients, respectively; hypopigmentation of the face, neck, and/or chest in 10.2% of patients (n = 9); diffuse hypopigmentation in 12.5% (n = 11); and acral hypopigmentation in 17% (n = 15). Diffuse hyperpigmentation was associated with diffuse SSc (P = .001), increased modified Rodnan skin score (P = .001), and shorter duration of Raynaud phenomenon (P = .002) in univariate analysis but not in multivariate analysis. Moreover, diffuse hyperpigmentation was associated with digital ulcers (P = .005), as confirmed by multivariate analysis (odds ratio, 2.96; 95% confidence interval, 1.28-6.89).
This was a single-center retrospective study of a cohort of patients with SSc.
Screening for skin pigmentation disorders could be useful in the management of patients with SSc to identify those with a high risk of development of digital ulcers, which is a symptom of vascular involvement in SSc.
系统性硬化症(SSc)的皮肤色素沉着障碍在文献中鲜有描述。然而,它们可能是诊断和/或严重程度的标志物。
评估色素沉着障碍与 SSc 患者系统性受累之间的关系。
共定义了 5 种皮肤色素沉着障碍模式:弥漫性色素沉着过度;暴露部位的色素沉着过度;头部、颈部和/或胸部上部的色素脱失;肢端色素沉着减退;弥漫性色素减退。
共纳入 239 例患者;88 例(36.8%)存在皮肤色素沉着障碍,分别为:弥漫性色素沉着过度和暴露部位色素沉着过度分别占 38.6%(n=34)和 27.3%(n=24);面部、颈部和/或胸部色素脱失占 10.2%(n=9);弥漫性色素减退占 12.5%(n=11);肢端色素减退占 17%(n=15)。在单因素分析中,弥漫性色素沉着过度与弥漫性 SSc(P=0.001)、改良 Rodnan 皮肤评分增加(P=0.001)和雷诺现象持续时间缩短(P=0.002)相关,但在多因素分析中则不然。此外,弥漫性色素沉着过度与手指溃疡相关(P=0.005),这一结果在多因素分析中得到了证实(优势比,2.96;95%置信区间,1.28-6.89)。
这是一项针对 SSc 患者队列的单中心回顾性研究。
筛查皮肤色素沉着障碍可能有助于 SSc 患者的管理,以识别那些发生手指溃疡风险较高的患者,这是 SSc 血管受累的一个症状。